Literature DB >> 34413963

Structure-Activity Relationship Studies Reveal New Astemizole Analogues Active against Plasmodium falciparum In Vitro.

Dickson Mambwe1, Malkeet Kumar1, Richard Ferger1, Dale Taylor2, Mathew Njoroge2, Dina Coertzen3, Janette Reader3, Mariëtte van der Watt3, Lyn-Marie Birkholtz3, Kelly Chibale1,2,4,5.   

Abstract

In the context of drug repositioning and expanding the existing structure-activity relationship around astemizole (AST), a new series of analogues were designed, synthesized, and evaluated for their antiplasmodium activity. Among 46 analogues tested, compounds 21, 30, and 33 displayed high activities against asexual blood stage parasites (PfNF54 IC50 = 0.025-0.043 μM), whereas amide compound 46 additionally showed activity against late-stage gametocytes (stage IV/V; PfLG IC50 = 0.6 ± 0.1 μM) and 860-fold higher selectivity over hERG (46, SI = 43) compared to AST. Several analogues displaying high solubility (Sol > 100 μM) and low cytoxicity in the Chinese hamster ovary (SI > 148) cell line have also been identified.
© 2021 American Chemical Society.

Entities:  

Year:  2021        PMID: 34413963      PMCID: PMC8366009          DOI: 10.1021/acsmedchemlett.1c00328

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.632


  16 in total

Review 1.  Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore.

Authors:  Fraser F Fleming; Lihua Yao; P C Ravikumar; Lee Funk; Brian C Shook
Journal:  J Med Chem       Date:  2010-08-30       Impact factor: 7.446

2.  Synthesis and anti-Plasmodium activity of benzimidazole analogues structurally related to astemizole.

Authors:  Gheorghe Roman; Ian E Crandall; Walter A Szarek
Journal:  ChemMedChem       Date:  2013-09-10       Impact factor: 3.466

3.  Mitigating hERG Inhibition: Design of Orally Bioavailable CCR5 Antagonists as Potent Inhibitors of R5 HIV-1 Replication.

Authors:  Renato Skerlj; Gary Bridger; Yuanxi Zhou; Elyse Bourque; Ernest McEachern; Sanjay Danthi; Jonathan Langille; Curtis Harwig; Duane Veale; Bryon Carpenter; Tuya Ba; Michael Bey; Ian Baird; Trevor Wilson; Markus Metz; Ron MacFarland; Renee Mosi; Veronique Bodart; Rebecca Wong; Simon Fricker; Dana Huskens; Dominique Schols
Journal:  ACS Med Chem Lett       Date:  2012-01-25       Impact factor: 4.345

4.  IV. Discovery of CXCR3 antagonists substituted with heterocycles as amide surrogates: improved PK, hERG and metabolic profiles.

Authors:  Anilkumar G Nair; Michael K C Wong; Youheng Shu; Yueheng Jiang; Chung-Her Jenh; Seong Heon Kim; De-Yi Yang; Qingbei Zeng; Yuefei Shao; Lisa Guise Zawacki; Jingqi Duo; Brian F McGuinness; Carolyn Diianni Carroll; Doug W Hobbs; Neng-Yang Shih; Stuart B Rosenblum; Joseph A Kozlowski
Journal:  Bioorg Med Chem Lett       Date:  2014-01-11       Impact factor: 2.823

5.  Astemizole analogues with reduced hERG inhibition as potent antimalarial compounds.

Authors:  Junjun Tian; Leen Vandermosten; Steve Peigneur; Lien Moreels; Jef Rozenski; Jan Tytgat; Piet Herdewijn; Philippe E Van den Steen; Steven De Jonghe
Journal:  Bioorg Med Chem       Date:  2017-10-07       Impact factor: 3.641

6.  Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study.

Authors:  Aline Uwimana; Noella Umulisa; Meera Venkatesan; Samaly S Svigel; Zhiyong Zhou; Tharcisse Munyaneza; Rafiki M Habimana; Anicet Rucogoza; Leah F Moriarty; Ryan Sandford; Emily Piercefield; Ira Goldman; Bryan Ezema; Eldin Talundzic; M Andreína Pacheco; Ananias A Escalante; Daniel Ngamije; Jean-Louis N Mangala; Michee Kabera; Kaendi Munguti; Monique Murindahabi; William Brieger; Clarisse Musanabaganwa; Leon Mutesa; Venkatachalam Udhayakumar; Aimable Mbituyumuremyi; Eric S Halsey; Naomi W Lucchi
Journal:  Lancet Infect Dis       Date:  2021-04-14       Impact factor: 25.071

7.  Chloroquine-astemizole hybrids with potent in vitro and in vivo antiplasmodial activity.

Authors:  Chitalu C Musonda; Gavin A Whitlock; Michael J Witty; Reto Brun; Marcel Kaiser
Journal:  Bioorg Med Chem Lett       Date:  2008-11-18       Impact factor: 2.823

8.  History of human parasitic diseases.

Authors:  Francis E G Cox
Journal:  Infect Dis Clin North Am       Date:  2004-06       Impact factor: 5.982

Review 9.  The past, present and future of anti-malarial medicines.

Authors:  Edwin G Tse; Marat Korsik; Matthew H Todd
Journal:  Malar J       Date:  2019-03-22       Impact factor: 2.979

10.  6-Cyano Analogues of Bedaquiline as Less Lipophilic and Potentially Safer Diarylquinolines for Tuberculosis.

Authors:  Amy S T Tong; Peter J Choi; Adrian Blaser; Hamish S Sutherland; Sophia K Y Tsang; Jerome Guillemont; Magali Motte; Christopher B Cooper; Koen Andries; Walter Van den Broeck; Scott G Franzblau; Anna M Upton; William A Denny; Brian D Palmer; Daniel Conole
Journal:  ACS Med Chem Lett       Date:  2017-09-22       Impact factor: 4.345

View more
  1 in total

1.  Systematic Analysis of Clemastine, a Candidate Apicomplexan Parasite-Selective Tubulin-Targeting Agent.

Authors:  Izra Abbaali; Danny A Truong; Shania D Day; Nancy Haro-Ramirez; Naomi S Morrissette
Journal:  Int J Mol Sci       Date:  2021-12-22       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.